Search hospitals

>

Ontario

>

KINGSTON

Kingston Health Sciences Centre

Claim this profile

KINGSTON, Ontario K7L 2V7

Global Leader in Cancer

Global Leader in Atrial Fibrillation

Conducts research for Breast Cancer

Conducts research for Lung Cancer

Conducts research for Prostate Cancer

341 reported clinical trials

38 medical researchers

Photo of Kingston Health Sciences Centre in KINGSTONPhoto of Kingston Health Sciences Centre in KINGSTONPhoto of Kingston Health Sciences Centre in KINGSTON

Summary

Kingston Health Sciences Centre is a medical facility located in KINGSTON, Ontario. This center is recognized for care of Cancer, Atrial Fibrillation, Breast Cancer, Lung Cancer, Prostate Cancer and other specialties. Kingston Health Sciences Centre is involved with conducting 341 clinical trials across 599 conditions. There are 38 research doctors associated with this hospital, such as Laura Wheaton, John Muscedere, MD, Elisa Brietzke, MD, PhD, and Stephanie Sibley, MD.

Area of expertise

1

Cancer

Global Leader

Kingston Health Sciences Centre has run 29 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Atrial Fibrillation

Global Leader

Kingston Health Sciences Centre has run 19 trials for Atrial Fibrillation.

Top PIs

Clinical Trials running at Kingston Health Sciences Centre

Breast Cancer

Cancer

Prostate Cancer

Testicular cancer

Pancreatic Cancer

Melanoma

Critical Illness

Ovarian Cancer

Traumatic Brain Injury

Asthma

Image of trial facility.

G-CSF Omission

for Breast Cancer

This trial is testing whether breast cancer patients can safely skip a medication during part of their chemotherapy. This medication helps with white blood cell recovery but can cause painful side effects. The study aims to see if omitting this medication can improve patients' quality of life without increasing infection risks.

Recruiting

3 awards

Phase 4

3 criteria

Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Kingston Health Sciences Centre?

Where is Kingston Health Sciences Centre located?

Who should I call to ask about financial aid or insurance network?

What insurance does Kingston Health Sciences Centre accept?

What awards or recognition has Kingston Health Sciences Centre received?